Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor
NCT02086721
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Solid Tumour
Interventions
DRUG:
L19-IL2
Sponsor
Maastricht Radiation Oncology